ARISTADA APPROVED 100515
- Thread starter anonymous
- Start date
-
- Tags
- None
Good Luckyou're all gonna need it.
Luck = prep matches up with opportunity
Good luck on getting the job (got it).
Good luck on getting approval (got it).
Good luck on selling Aristada (thanks!).
Pretty intelligent retort! You must be that great lawyer the reps were referencing from Otsuka.
So it rebounded! The entire market dropped early on, biotech significantly. ALKS was down 8% earlier in the trading session. Very nice come back! Very promising future ahead.
Congrats to all Alkermesians! Have fun with the launch- it's the most fun in pharma sales.
They are the same medications (Abilify Maintena and Alkermes Aristada) just in different patented packaging (tiny injectable capsules that release the medications over time).
From a practical standpoint the only difference is this:
Abilify Maintena is available in 1 injection per month
Aklermes Aristada is available in 1 injection per 4 weeks, or 6 weeks
From a practical standpoint the only difference is this:
Abilify Maintena is available in 1 injection per month
Aklermes Aristada is available in 1 injection per 4 weeks, or 6 weeks
I wonder if this makes Alkermes a serious buyout target now? Thoughts?
So I guess you didn't get the response you were looking for on Yahoo board? Keep trying troll.
Nope. Thought I would ask what you guys were thinking. I am in the industry and also play the stocks. So just doing some homework. Your dumb, immature response indicates to me that your company sure has some jerks in it. Now I hope you get bought, laid off and end up back at Enterprise renting out cars to real pharma professionals.
You dick.
You don't seem to be smart enough to play the market but highly likely to be good at playing with yourself. Back to the otsuka board little boy.
Compared to Abilify Maintena, Aristada’s label also requires one additional oral Aripiprazole dose during the initiation of therapy. Also, Invega Trinza was approved by the FDA on May 19, 2015, as the first and only schizophrenia drug that is administered only four times a year—a dosing interval higher than that approved for Aristada. These factors could make Aristada less attractive to the patient and physician community